Please login to the form below

Not currently logged in

Orkambi special

This page shows the latest Orkambi special news and features for those working in and with pharma, biotech and healthcare.

Orkambi row: government now considering Crown Use licensing

Orkambi row: government now considering Crown Use licensing

MPs call for radical solutions as deadlock remains. Vertex is under renewed pressure to reach agreement with NHS England on its cystic fibrosis drug Orkambi, with a government minister yesterday warning ... Yesterday saw MPs in the House of Commons take

Latest news

  • Still no breakthrough on Orkambi talks, MPs want answers Still no breakthrough on Orkambi talks, MPs want answers

    The deadlock over access to Orkambi has now reached its three year milestone, thanks to a clash between NICE and NHS England and Vertex over the price of the drug. ... The parliamentary health select committee called a special hearing on the Orkambi row

More from news
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • The Orkambi row explained The Orkambi row explained

    Is the UK an extreme outlier in terms of market access for Orkambi? ... October 2016: Orkambi negotiations between Vertex, the UK government and the NHS get underway.

  • #OrkambiNow? #OrkambiNow?

    For example in Germany, from the time of European licensing, adults and children of 12 and over were able to access Orkambi if they had the right mutations.”. ... engage. However it’s equally evident that the Orkambi case also produced some serious

More from intelligence
Approximately 2 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company
Spirit, an OPEN Health Company

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

Box 1
Strategic commitment
KOL Ambassador Program & Podcast Creation: A Customer Story
Animation: Living With
The journey from the patient's perspective...